R&D | May 25, 2026
Sumitomo Pharma unveils new COURAGE & OPTYX data at AUA 2026
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The George Institute India’s large-scale community-based model demonstrates reduced depression, self-harm, and suicide risk among adolescents in Delhi and Vijayawada
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Subscribe To Our Newsletter & Stay Updated
